Vaidya Sane Ayurved Laboratories Ltd

As of November 6, 2025, Vaidya Sane is considered very expensive and overvalued with a PE ratio of 48.20 and an EV to EBITDA of 26.00, significantly higher than its peers like Sun Pharma and Cipla, despite a strong year-to-date return of 90.47%.

Vaidya Sane has shown significant growth from Mar'22 to Mar'25, with net sales rising to 89.85 Cr despite a decline from the previous year, and profit before tax increasing to 9.90 Cr. The company improved its operating profit and earnings per share, indicating a strong upward trend in revenue and profitability.

As of 29-Oct, Vaidya Sane Ayurved Laboratories Ltd is seeing a price increase to 274.95, with a 1.08% rise and strong performance metrics, including a year-to-date increase of 98.45%. The stock is outperforming the benchmark Sensex and has experienced significant investor interest, reflected in a 61.76% rise in delivery volume.

As of 15-Oct, Vaidya Sane Ayurved Laboratories Ltd's stock price is declining at 259.10, down 4.04%, and has underperformed its sector today. Despite a strong long-term performance with a year-to-date return of +87.01%, recent trends indicate challenges in maintaining momentum against broader market gains.

As of October 10, 2025, Vaidya Sane is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 49.32 and high EV to EBITDA ratio of 26.37, especially when compared to peers like Sun Pharma and Cipla, despite a strong year-to-date stock return of 94.88%.

As of October 10, 2025, Vaidya Sane is considered overvalued with a PE ratio of 49.32, significantly higher than its peers like Sun Pharma and Cipla, despite impressive year-to-date returns of 94.88%.

As of October 10, 2025, Vaidya Sane is considered overvalued with a valuation grade of expensive, reflected by a high PE ratio of 49.32 compared to peers like Sun Pharma and Cipla, despite impressive year-to-date returns of 94.88%.

As of October 7, 2025, Vaidya Sane is considered very expensive with a PE ratio of 52.37 and significantly higher valuation metrics compared to peers like Sun Pharma and Cipla, indicating it may be overvalued despite a strong year-to-date return of 106.93%.

As of October 6, 2025, Vaidya Sane is considered overvalued with a valuation grade of expensive, reflected by a high PE ratio of 50.05 and significant premiums compared to peers like Sun Pharma and Cipla, despite a strong year-to-date return of 97.76%.

As of 26-Sep, Vaidya Sane Ayurved Laboratories Ltd's stock price is at 278.00, down 4.14%. Despite recent declines and reduced trading activity, the stock has shown strong long-term growth with a 91.72% return over the past year.

As of September 25, 2025, Vaidya Sane is considered overvalued with a PE ratio of 52.97 and an EV to EBITDA of 28.44, significantly higher than peers like Sun Pharma and Cipla, despite a year-to-date stock performance of 109.31% compared to the Sensex's 5.27%.

As of September 24, 2025, Vaidya Sane is considered very expensive and overvalued with a PE ratio of 53.61 and an EV to EBITDA of 28.80, significantly higher than peers like Sun Pharma and Cipla, despite a strong YTD return of 111.84%.

As of 24-Sep, Vaidya Sane Ayurved Laboratories Ltd is experiencing a price increase to 293.50, reflecting a 4.99% rise. The stock has shown strong performance with a 99.32% return over the past year, outperforming the BSE500 index, and maintains a positive trend despite a recent decline in investor participation.